AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR -mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications Jg. 10; H. 1; S. 259 - 14
Hauptverfasser: Taniguchi, Hirokazu, Yamada, Tadaaki, Wang, Rong, Tanimura, Keiko, Adachi, Yuta, Nishiyama, Akihiro, Tanimoto, Azusa, Takeuchi, Shinji, Araujo, Luiz H., Boroni, Mariana, Yoshimura, Akihiro, Shiotsu, Shinsuke, Matsumoto, Isao, Watanabe, Satoshi, Kikuchi, Toshiaki, Miura, Satoru, Tanaka, Hiroshi, Kitazaki, Takeshi, Yamaguchi, Hiroyuki, Mukae, Hiroshi, Uchino, Junji, Uehara, Hisanori, Takayama, Koichi, Yano, Seiji
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 16.01.2019
Nature Publishing Group
Nature Portfolio
Schlagworte:
ISSN:2041-1723, 2041-1723
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!